Found: 19
Select item for more details and to access through your institution.
Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 7, p. 1214, doi. 10.1002/psp4.13153
- By:
- Publication type:
- Article
Optimization of trial duration to predict long‐term HbA1c change with therapy: A pharmacometrics simulation‐based evaluation.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 11, p. 1443, doi. 10.1002/psp4.12854
- By:
- Publication type:
- Article
Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 2, p. 234, doi. 10.1002/jcph.1728
- By:
- Publication type:
- Article
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
- Published in:
- 2016
- By:
- Publication type:
- letter
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
- Published in:
- Diabetes Care, 2016, v. 39, n. 11, p. e199, doi. 10.2337/dci16-0030
- By:
- Publication type:
- Article
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects.
- Published in:
- Diabetes Care, 2014, v. 37, n. 9, p. 2609, doi. 10.2337/dc14-0210
- By:
- Publication type:
- Article
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1193, doi. 10.1111/dom.13215
- By:
- Publication type:
- Article
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 419, doi. 10.1111/dom.13087
- By:
- Publication type:
- Article
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 11, p. 1521, doi. 10.1111/dom.12958
- By:
- Publication type:
- Article
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 8, p. 1071, doi. 10.1111/dom.12904
- By:
- Publication type:
- Article
Novel hepato-preferential basal insulin peglispro ( BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 482, doi. 10.1111/dom.12834
- By:
- Publication type:
- Article
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 4, p. 751, doi. 10.1002/cpt.2988
- By:
- Publication type:
- Article
348-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia across a Range of Nadir Blood Glucose Levels.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-348-P
- By:
- Publication type:
- Article
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 3, p. 377, doi. 10.1007/s40272-023-00565-y
- By:
- Publication type:
- Article
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.
- Published in:
- 2016
- By:
- Publication type:
- journal article
18. Glucagon Receptor Antibody LY2786890 Reduced Glucose Levels in Type 2 Diabetes Mellitus Patients (106-LB).
- Published in:
- Nederlands Tijdschrift voor Diabetologie (NTvD), 2015, v. 13, n. 3, p. 73, doi. 10.1007/s12467-015-0039-4
- By:
- Publication type:
- Article
Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 4, p. 699, doi. 10.1002/cpt.998
- By:
- Publication type:
- Article